Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly (LLY) and Johnson & Johnson (NYSE:JNJ) while downgrading Bristol Myers (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV).

Eli Lilly (LLY) has